

Dabrafenib and trametinib versus dabrafenib and placebo in metastatic melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Lancet, The

386, 444-451

DOI: [10.1016/s0140-6736\(15\)60898-4](https://doi.org/10.1016/s0140-6736(15)60898-4)

Citation Report

#	ARTICLE	IF	CITATIONS
2	The Forecast Is Bright: Recent Advances in Melanoma Treatment / Perspectives prometteuses: R�centes perspectives dans le traitement des m�lanomes. Journal of Cutaneous Medicine and Surgery, 2015, 19, 435-439.	0.6	0
3	Novel melanoma therapy. Experimental Hematology and Oncology, 2015, 5, 23.	2.0	8
8	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.1	4
9	Systemic therapy of metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1237.	0.4	12
10	Systemtherapie des metastasierten malignen Melanoms. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1238.	0.4	7
11	A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting. British Journal of Dermatology, 2015, 173, 1462-1470.	1.4	24
12	Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma. Journal of Surgical Oncology, 2015, 112, 844-845.	0.8	6
13	Trametinib: a MEK inhibitor for management of metastatic melanoma. OncoTargets and Therapy, 2015, 8, 2251.	1.0	91
14	Prognostic score for patients with advanced melanoma treated with ipilimumab. European Journal of Cancer, 2015, 51, 2785-2791.	1.3	53
15	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1396-1403.	0.5	76
16	Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. Expert Opinion on Pharmacotherapy, 2015, 16, 2257-2263.	0.9	9
18	Inhibition of BRAF and MEK in BRAF-mutant melanoma. Lancet, The, 2015, 386, 410-412.	6.3	8
19	Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Critical Reviews in Oncology/Hematology, 2015, 96, 385-398.	2.0	51
21	Hitting the Target in BRAF-Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 3990-3992.	0.8	12
22	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget, 2016, 7, 25135-25149.	0.8	6
23	Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma. OncoTargets and Therapy, 2016, 9, 2725.	1.0	18
24	Burden of Illness for Metastatic Melanoma in Canada, 2011-2013. Current Oncology, 2016, 23, 563-570.	0.9	16
25	Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?. Reviews on Recent Clinical Trials, 2016, 11, 81-86.	0.4	12

#	ARTICLE	IF	CITATIONS
26	Management of Melanoma Therapy-Associated Toxicities. , 2016, , 299-319.		1
27	Optimal Selection of Targeted Therapies for Melanoma Patients. , 2016, , 169-183.		0
28	Tumor Heterogeneity and Therapeutic Resistance. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e585-e593.	1.8	30
29	Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer. Journal of Thoracic Disease, 2016, 8, 2369-2371.	0.6	3
30	BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy. OncoTargets and Therapy, 2016, Volume 9, 7149-7159.	1.0	33
31	The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Frontiers in Cell and Developmental Biology, 2016, 4, 33.	1.8	84
32	Cytostatic Agentsâ€”Tyrosine Kinase Inhibitors Utilized in the Treatment of Solid Malignancies. Side Effects of Drugs Annual, 2016, 38, 479-491.	0.6	1
33	Cutaneous melanoma â€“ guidelines for diagnostics and therapy in 2016. Przegląd Dermatologiczny, 2016, 1, 1-18.	0.0	0
35	The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. Current Opinion in Oncology, 2016, 28, 185-191.	1.1	17
36	The proportion cured of patients diagnosed with Stage IIIâ€“IV cutaneous malignant melanoma in <scp>S</scp>weden 1990â€“2007: A populationâ€based study. International Journal of Cancer, 2016, 138, 2829-2836.	2.3	8
37	Update on immune therapy in melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 799-808.	0.5	0
38	The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resistance Updates, 2016, 28, 28-42.	6.5	24
39	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. Archives of Pathology and Laboratory Medicine, 2016, 140, 355-357.	1.2	9
40	Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden. International Journal of Cancer, 2016, 139, 543-553.	2.3	11
41	Melanoma therapy: Check the checkpoints. Journal of Dermatology, 2016, 43, 121-124.	0.6	13
42	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	2.3	76
43	Major Changes in Systemic Therapy for Advanced Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 638-640.	2.3	8
44	Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. International Journal of Oncology, 2016, 49, 1164-1174.	1.4	52

#	ARTICLE	IF	CITATIONS
45	Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review). <i>Oncology Reports</i> , 2016, 36, 1779-1786.	1.2	14
46	Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. , 2016, 4, 44.		54
47	Optimizing combination dabrafenib and trametinib therapy in BRAF mutationâ€”positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 5-12.	0.7	22
48	Advancements in unresectable melanoma: a multidisciplinary perspective. <i>Melanoma Management</i> , 2016, 3, 171-175.	0.1	0
49	The cutting edge of metastatic melanoma therapy. <i>Melanoma Management</i> , 2016, 3, 217-229.	0.1	1
50	Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab. <i>Journal of Immunotherapy</i> , 2016, 39, 373-378.	1.2	19
51	Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand. <i>Seminars in Oncology</i> , 2016, 43, 625-637.	0.8	13
52	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. <i>Immunotherapy</i> , 2016, 8, 681-686.	1.0	1
53	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. <i>European Journal of Cancer</i> , 2016, 62, 76-85.	1.3	178
54	What Is New in Melanoma Genetics and Treatment?. <i>Dermatology</i> , 2016, 232, 259-264.	0.9	25
55	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. <i>Current Oncology Reports</i> , 2016, 18, 42.	1.8	54
56	Improving patient outcomes to targeted therapies in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 633-641.	1.1	6
58	Pembrolizumab for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 867-873.	0.5	10
59	<i>BRAF</i> V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAFâ€”MEK Combination Therapy. <i>Cancer Discovery</i> , 2016, 6, 594-600.	7.7	75
60	Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma. <i>Pharmacological Research</i> , 2016, 107, 42-47.	3.1	26
61	Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1479-1489.	0.3	56
62	Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. <i>Future Oncology</i> , 2016, 12, 1331-1344.	1.1	24
63	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	1.3	8

#	ARTICLE	IF	CITATIONS
64	Targeted therapy in BRAF-mutated lung adenocarcinoma. <i>Lancet Oncology</i> , The, 2016, 17, 550-551.	5.1	1
65	Emerging targeted therapies for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 195-207.	1.0	22
66	Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. <i>Journal of Medical Economics</i> , 2016, 19, 900-912.	1.0	30
67	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. <i>Physiological Reviews</i> , 2016, 96, 805-829.	13.1	49
68	Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 781-796.	1.9	12
69	A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1157-1164.	1.1	22
70	Genetics of Melanoma. , 2016, , .		3
71	Biology and treatment of BRAF mutant metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 33-45.	0.1	28
72	Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2016, 18, 67.	1.8	10
73	Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i> <sup>V600</sup> mutated melanoma. <i>Melanoma Management</i> , 2016, 3, 207-216.	0.1	21
74	Combination therapeutics in complex diseases. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2231-2240.	1.6	76
75	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
76	A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2016, 68, 1-10.	1.3	9
78	Adult Cancers in Adolescents and Young Adults. <i>Progress in Tumor Research</i> , 2016, 43, 64-73.	0.1	3
79	The Systemic Management of Advanced Melanoma in 2016. <i>Oncology Research and Treatment</i> , 2016, 39, 635-642.	0.8	15
80	The future of melanoma therapy: developing new drugs and improving the use of old ones. <i>Future Oncology</i> , 2016, 12, 2531-2534.	1.1	7
81	Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1248-1260.	5.1	832
82	Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 221-233.	0.4	15

#	ARTICLE	IF	CITATIONS
83	MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. <i>European Journal of Cancer</i> , 2016, 65, 130-138.	1.3	55
84	BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. <i>Cancer Medicine</i> , 2016, 5, 1183-1193.	1.3	41
85	Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. <i>International Journal of Cancer</i> , 2016, 139, 1195-1201.	2.3	41
86	Multiple roles of NF1 in the melanocyte lineage. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 417-425.	1.5	16
87	Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 679-687.	1.5	8
88	Applied Immunohistochemistry in the Evaluation of Skin Neoplasms. , 2016, , .		1
89	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. <i>Clinical Cancer Research</i> , 2016, 22, 6088-6098.	3.2	43
90	Stratified Treatment in Lung Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 760-766.	0.8	13
91	Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. <i>Annals of Oncology</i> , 2016, 27, 2288-2294.	0.6	117
92	Intralesional and systemic immunotherapy for metastatic melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1491-1499.	1.4	15
93	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	1.5	102
94	Increased immunity and BRAF inhibition: Yet another argument for combination therapy?. <i>Pharmacological Research</i> , 2016, 113, 719-720.	3.1	2
95	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 811-826.	1.1	26
96	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	5.1	266
97	Targeted therapy and elderly people: A review. <i>European Journal of Cancer</i> , 2016, 69, 199-215.	1.3	34
98	An Open-Label, Dose Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5204-5210.	3.2	19
99	Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma. <i>Oncology and Therapy</i> , 2016, 4, 239-256.	1.0	8
100	The combination of vemurafenib and cobimetinib in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1105-1111.	0.5	3

#	ARTICLE	IF	CITATIONS
101	Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. <i>Scientific Reports</i> , 2016, 6, 26803.	1.6	14
102	Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. <i>Cancer Research</i> , 2016, 76, 6253-6265.	0.4	46
103	Combined Therapy with Dabrafenib and Trametinib in BRAF-Mutated Metastatic Melanoma in a Real-Life Setting: The INT Milan Experience. <i>Tumori</i> , 2016, 102, 501-507.	0.6	6
104	News From the Society of Surgical Oncology (SSO) Annual Cancer Symposium (March 15-18, 2017) Tj ETQq1 1 0.784314 rgBT /Over Clinical Skin Cancer, 2016, 1, 57-58.	0.1	0
105	Importance and methods of searching for E-publications ahead of print in systematic reviews. <i>Evidence-Based Medicine</i> , 2016, 21, 55-59.	0.6	9
106	Post ASCO update 2016 lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 215-218.	0.3	0
107	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. , 2016, 4, 85.		18
108	BRAF-Directed Therapy in Metastatic Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 175-178.	1.0	31
109	Drug interaction between dabrafenib and immunosuppressive drugs: about one case. <i>Melanoma Research</i> , 2016, 26, 532-534.	0.6	4
110	Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. <i>Melanoma Research</i> , 2016, 26, 382-386.	0.6	31
111	Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation. <i>Targeted Oncology</i> , 2016, 11, 417-428.	1.7	37
112	Treatment of elderly patients with melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 13-16.	0.3	0
113	Talimogene laherparepvec in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 781-788.	0.5	0
114	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology, The</i> , 2016, 17, 984-993.	5.1	689
115	Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. <i>Lancet Oncology, The</i> , 2016, 17, 1037-1039.	5.1	26
116	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016, 14, 95.	1.8	117
117	Combined BRAF and MEK inhibition in BRAF-mutant NSCLC. <i>Lancet Oncology, The</i> , 2016, 17, 860-862.	5.1	5
118	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	2.9	256

#	ARTICLE	IF	CITATIONS
119	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396.	1.4	35
120	IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. <i>Cancer Research</i> , 2016, 76, 2561-2572.	0.4	26
121	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016, 29, 270-284.	7.7	198
122	Combination Therapies for Melanoma: A New Standard of Care?. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 99-105.	3.3	23
123	New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. <i>Current Oncology Reports</i> , 2016, 18, 18.	1.8	12
124	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncimmunology</i> , 2016, 5, e1136044.	2.1	55
126	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv414.	3.0	81
127	Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 245-251.	1.4	64
128	The impact of sequencing on diagnosis and treatment of malignant melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 423-433.	1.5	4
129	Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. <i>European Journal of Cancer</i> , 2016, 57, 112-117.	1.3	14
130	A Novel RAF Kinase Inhibitor with DFG-Out Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 354-365.	1.9	66
132	Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. <i>Cancer Treatment Reviews</i> , 2016, 45, 38-45.	3.4	71
133	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.3	19
134	Ocular toxicities of MEK inhibitors and other targeted therapies. <i>Annals of Oncology</i> , 2016, 27, 998-1005.	0.6	72
135	Selumetinib for the treatment of melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 223-231.	0.5	1
136	Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. <i>Future Oncology</i> , 2016, 12, 95-106.	1.1	15
137	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	1.3	137
138	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016, 39, 30-38.	2.4	23



#	ARTICLE	IF	CITATIONS
139	Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 48-56.	1.4	240
140	Metastatic melanoma treatment: Combining old and new therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 242-253.	2.0	64
141	Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 172-183.	1.9	35
142	The influence of subclonal resistance mutations on targeted cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 335-347.	12.5	185
143	<i>BRAF</i> V600 mutational status affects recurrence patterns of melanoma brain metastasis. <i>International Journal of Cancer</i> , 2017, 140, 2716-2727.	2.3	24
144	Pulmonary sarcoid-like granulomatosis induced by nivolumab. <i>British Journal of Dermatology</i> , 2017, 176, 1060-1063.	1.4	106
145	Combine and conquer: challenges for targeted therapy combinations in early phase trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 57-66.	12.5	239
146	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. <i>BioDrugs</i> , 2017, 31, 51-61.	2.2	46
147	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 6-16.	0.2	14
148	KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. <i>Medical Oncology</i> , 2017, 34, 26.	1.2	94
149	Cell cycle tailored targeting of metastatic melanoma: Challenges and opportunities. <i>Experimental Dermatology</i> , 2017, 26, 649-655.	1.4	20
150	Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. <i>Chinese Journal of Cancer</i> , 2017, 36, 10.	4.9	38
151	Metformin monotherapy in melanoma: a pilot, open label, prospective, and multicentric study indicates no benefit. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 378-380.	1.5	23
152	Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 1378-1385.	0.7	17
153	The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 53-75.	2.7	30
154	Towards therapeutic advances in melanoma management: An overview. <i>Life Sciences</i> , 2017, 174, 50-58.	2.0	47
155	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 303-310.	3.3	12
156	BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 9.	1.3	51

#	ARTICLE	IF	CITATIONS
157	Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years. <i>Value in Health</i> , 2017, 20, 593-601.	0.1	16
158	Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 487-495.	0.9	7
159	Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 129-143.	0.9	3
160	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. <i>European Journal of Cancer</i> , 2017, 75, 169-178.	1.3	96
161	BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. <i>American Journal of Kidney Diseases</i> , 2017, 70, 145-150.	2.1	25
162	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2017, 18, 464-472.	5.1	139
163	The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2017, 75, 268-279.	1.3	62
164	Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 43-50.	2.7	23
165	Mucosal melanoma of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 136-152.	2.0	125
167	Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2980-2992.	1.1	25
168	Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1638-1640.	1.3	12
169	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 597-611.	3.3	11
170	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1283462.	2.1	34
171	Baseline $\beta$ -catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. <i>European Journal of Cancer</i> , 2017, 78, 70-81.	1.3	42
172	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. <i>Science Advances</i> , 2017, 3, e1600957.	4.7	10
173	Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. <i>Nature Communications</i> , 2017, 8, 15086.	5.8	107
174	Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1596-1609.	1.9	59
175	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017, 79, 176-184.	1.3	31

#	ARTICLE	IF	CITATIONS
176	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	0.6	549
177	Use of precision methods to accelerate drug development in oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 109-120.	0.4	0
178	A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. <i>Cancer Medicine</i> , 2017, 6, 1143-1153.	1.3	60
179	Prognostic risk factors of first recurrence in patients with primary stages II cutaneous malignant melanoma from the population-based Swedish melanoma register. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1468-1474.	1.3	24
180	A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Teme sirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 576-588.	1.2	10
181	Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma. <i>CNS Oncology</i> , 2017, 6, 5-9.	1.2	35
182	Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 43-54.	1.0	70
183	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5339-5348.	3.2	142
184	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 31-35.	1.2	85
185	Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. <i>Oncologist</i> , 2017, 22, 786-796.	1.9	95
186	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. <i>Oncologist</i> , 2017, 22, 963-971.	1.9	145
187	Somatic driver mutations in melanoma. <i>Cancer</i> , 2017, 123, 2104-2117.	2.0	96
188	S3 Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, e1-e41.	0.4	29
189	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	1.3	160
190	Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1658-1668.	1.9	16
191	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	5.1	561
192	MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 745-754.	3.3	104
193	Ubiquitination in melanoma pathogenesis and treatment. <i>Cancer Medicine</i> , 2017, 6, 1362-1377.	1.3	24

#	ARTICLE	IF	CITATIONS
194	Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. <i>Cancer</i> , 2017, 123, 2118-2129.	2.0	121
195	Molecular insights into melanoma brain metastases. <i>Cancer</i> , 2017, 123, 2163-2175.	2.0	34
196	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	2.0	24
197	Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. , 2017, 179, 127-141.		64
198	A review of binimetinib for the treatment of mutant cutaneous melanoma. <i>Future Oncology</i> , 2017, 13, 1755-1766.	1.1	35
199	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945
200	Recurrent tattoo reactions in a patient treated with <scp>BRAF</scp> and <scp>MEK</scp> inhibitors. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e375-e377.	1.3	8
201	Research progress in advanced melanoma. <i>Cancer Letters</i> , 2017, 397, 120-126.	3.2	34
202	Do the Side Effects of BRAF Inhibitors Mimic RASopathies?. <i>Journal of Investigative Dermatology</i> , 2017, 137, 805-809.	0.3	8
203	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 67-77.	3.3	112
205	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 35-42.	2.7	35
206	Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. <i>Annals of Oncology</i> , 2017, 28, 634-641.	0.6	179
207	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
208	Introduction to the special issue of <i>European Journal of Surgical Oncology</i> : New roads in melanoma management. <i>European Journal of Surgical Oncology</i> , 2017, 43, 513-516.	0.5	4
209	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 46-58.	1.4	27
210	Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. <i>Laboratory Investigation</i> , 2017, 97, 166-175.	1.7	37
211	Dabrafenib and trametinib in <i>BRAFV600E</i> mutated glioma. <i>CNS Oncology</i> , 2017, 6, 291-296.	1.2	58
212	Precision oncology: neither a silver bullet nor a dream. <i>Pharmacogenomics</i> , 2017, 18, 1525-1539.	0.6	21

#	ARTICLE	IF	CITATIONS
213	Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth. <i>Cancer Gene Therapy</i> , 2017, 24, 401-408.	2.2	1
214	Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. <i>Advances in Radiation Oncology</i> , 2017, 2, 572-580.	0.6	63
215	Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. <i>Clinical and Translational Radiation Oncology</i> , 2017, 6, 25-30.	0.9	5
216	Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors. <i>Cancer Research</i> , 2017, 77, 6240-6252.	0.4	98
217	The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. <i>Lasers in Medical Science</i> , 2017, 32, 1935-1939.	1.0	2
218	Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2351-2363.	1.9	166
219	Quality of life outcomes in patients with advanced melanoma: A review of the literature. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 511-520.	1.5	16
220	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
221	Intermittent Dosing of Dabrafenib and Trametinib in Metastatic <i>BRAF</i> <sup>V600E</sup> Mutated Papillary Thyroid Cancer: Two Case Reports. <i>Thyroid</i> , 2017, 27, 1201-1205.	2.4	14
222	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. <i>BMJ Open</i> , 2017, 7, e014880.	0.8	18
223	Binimetinib for the treatment of NRAS-mutant melanoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 985-990.	1.1	21
224	Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. <i>Current Opinion in Oncology</i> , 2017, 29, 484-492.	1.1	58
225	An Update on Randomized Clinical Trials in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 559-586.	0.6	1
226	Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
227	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1307-1316.	5.1	889
228	Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism. <i>Cardiovascular Toxicology</i> , 2017, 17, 487-493.	1.1	62
229	Update on the clinical use of kinase inhibitors in melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 887-893.	0.4	9
230	Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. <i>Oncology</i> , 2017, 93, 164-176.	0.9	6

#	ARTICLE	IF	CITATIONS
231	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 6054-6061.	3.2	75
232	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 6203-6214.	3.2	36
233	Liquid Biopsy: Value for Melanoma Therapy?. <i>Oncology Research and Treatment</i> , 2017, 40, 430-434.	0.8	9
234	Approaches to identify kinase dependencies in cancer signalling networks. <i>FEBS Letters</i> , 2017, 591, 2577-2592.	1.3	11
235	Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. <i>Clinica Chimica Acta</i> , 2017, 472, 26-29.	0.5	32
236	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	5.1	211
237	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	0.6	201
239	A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 790-803.	1.6	38
240	Novel Targeted Therapies for Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 54-58.	1.0	19
241	Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission. <i>Melanoma Research</i> , 2017, 27, 503-506.	0.6	3
242	Challenges in Conducting Clinical Research on Patients With Advanced Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 75-78.	1.0	2
243	Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 59-62.	1.0	9
244	Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. <i>Oncology</i> , 2017, 93, 249-258.	0.9	19
245	Advances in the Management of Melanoma. <i>Current Dermatology Reports</i> , 2017, 6, 288-296.	1.1	1
246	Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. <i>Melanoma Research</i> , 2017, 27, 545-557.	0.6	6
247	Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. <i>Oncologist</i> , 2017, 22, 823-833.	1.9	69
248	Perioperative BRAF inhibitors in locally advanced stage III melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 856-861.	0.8	11
250	Primary oral malignant melanoma metastasis to the brain and breast: A case report and literature review. <i>Oncology Letters</i> , 2017, 14, 1275-1280.	0.8	12

#	ARTICLE	IF	CITATIONS
251	The new paradigm of systemic therapies for metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 356-368.	0.6	34
252	The role for chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2017, 4, 125-136.	0.1	26
254	BRAF-MEK inhibition in melanoma brain metastases: a new hope. <i>Lancet Oncology</i> , The, 2017, 18, 836-837.	5.1	5
255	Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. <i>Npj Systems Biology and Applications</i> , 2017, 3, 14.	1.4	45
256	Erythema Nodosum-like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib. <i>Clinical Nuclear Medicine</i> , 2017, 42, 44-46.	0.7	14
257	Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. <i>Journal of Translational Medicine</i> , 2017, 15, 146.	1.8	36
258	The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 82.	0.4	13
259	Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. <i>Current Medical Research and Opinion</i> , 2017, 33, 1663-1675.	0.9	9
260	Combinatorial immunotherapy for melanoma. <i>Cancer Gene Therapy</i> , 2017, 24, 141-147.	2.2	24
261	Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 113-117.	2.0	31
262	Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. <i>European Journal of Cancer Care</i> , 2017, 26, e12600.	0.7	17
263	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40
264	Immunotherapy in melanoma: Recent advances and future directions. <i>European Journal of Surgical Oncology</i> , 2017, 43, 604-611.	0.5	216
265	Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma. <i>JAMA Oncology</i> , 2017, 3, 366.	3.4	68
266	Developments in targeted therapy in melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 581-593.	0.5	45
267	(Neo)adjuvant systemic therapy for melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 534-543.	0.5	52
268	Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 6-16.	0.2	31
269	Cobimetinib. <i>Annals of Pharmacotherapy</i> , 2017, 51, 146-153.	0.9	35



#	ARTICLE	IF	CITATIONS
270	Successful strategy to treat a solitary cystic melanoma brain metastasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e216-e217.	1.3	0
271	Improvement of overall survival in stage IV melanoma patients during 2011â€“2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). Journal of Cancer Research and Clinical Oncology, 2017, 143, 533-540.	1.2	41
272	Are we entering the era of combination therapy for melanoma?. Melanoma Management, 2017, 4, 5-8.	0.1	0
273	Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis, 2017, 6, e385-e385.	2.1	56
274	Melanoma cutÃ¡neo cervicofacial. EMC - OtorrinolaringologÃ¡a, 2017, 46, 1-9.	0.0	0
275	Melanomi cutanei cervicofacciali. EMC - Otorinolaringoiatria, 2017, 16, 1-9.	0.0	0
277	Dabrafenib plus trametinib for compassionate use in metastatic melanoma. Medicine (United States), 2017, 96, e9523.	0.4	6
278	MAPK Pathwayâ€“Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma. Clinical Journal of Oncology Nursing, 2017, 21, 699-709.	0.3	15
279	Die Systemtherapie des fortgeschrittenen Melanoms im Jahr 2016. Karger Kompass Dermatologie, 2017, 5, 126-133.	0.0	0
280	Matrix Metalloproteinases in Melanoma with and without Regression. , 2017, , .		0
281	Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy. European Journal of Dermatology, 2017, 27, 548-549.	0.3	0
282	Overcoming resistance to BRAF inhibitors. Annals of Translational Medicine, 2017, 5, 387-387.	0.7	109
283	Systemic Therapy Options for Patients With Unresectable Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 661-672.	1.8	8
284	Clinical Nurse Consultant Support: Management of Patients With Melanoma Receiving Immunotherapy and Targeted Therapy. , 2017, 21, E93-E98.		3
285	Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim Melanom. JDDG - Journal of the German Society of Dermatology, 2017, 15, 887-894.	0.4	5
286	Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. Oncotarget, 2017, 8, 35761-35775.	0.8	23
287	Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. Patient Preference and Adherence, 2017, Volume 11, 1389-1399.	0.8	23
288	Circulating tumour DNA: analytical aspects and clinical applications for metastatic melanoma patients. Annales De Biologie Clinique, 2017, 75, 619-630.	0.2	7



#	ARTICLE	IF	CITATIONS
289	Current Development Status of MEK Inhibitors. <i>Molecules</i> , 2017, 22, 1551.	1.7	174
290	Dabrafenib. , 2017, , 505-530.		0
291	Trametinib. , 2017, , 531-559.		0
292	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2017, 7, 230.	1.3	43
293	Systemic Treatment of Metastatic Conjunctival Melanoma. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-3.	0.2	26
294	Therapeutic efficacy and safety of combined <em>BRAF</em> and MEK inhibition in patients with malignant melanoma: a meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5391-5403.	1.0	12
295	Therapy of Melanoma. , 2017, , 91-142.		0
296	Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. <i>BMC Cancer</i> , 2017, 17, 649.	1.1	12
297	Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report. <i>BMC Research Notes</i> , 2017, 10, 320.	0.6	7
298	High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74.		45
299	Variation of mutant allele frequency in NRAS Q61 mutated melanomas. <i>BMC Dermatology</i> , 2017, 17, 9.	2.1	19
300	Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect. <i>Case Reports in Dermatology</i> , 2017, 9, 80-85.	0.3	10
301	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. <i>Oncotarget</i> , 2017, 8, 78174-78192.	0.8	75
302	First-line treatment of metastatic melanoma: role of nivolumab. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 1-10.	2.7	26
303	Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. <i>Oncotarget</i> , 2017, 8, 60094-60108.	0.8	85
304	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	0.8	454
305	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
306	Chronic Kidney Disease as a Complication of Cancer. <i>Journal of Onco-Nephrology</i> , 2017, 1, 74-80.	0.3	2

#	ARTICLE	IF	CITATIONS
307	Current biologics for treatment of biliary tract cancers. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 430-440.	0.6	33
308	Promising therapeutics of gastrointestinal cancers in clinical trials. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 524-533.	0.6	1
309	Adjuvant Therapy in the Treatment of Melanoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1807-1813.	0.7	7
310	Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. <i>Clinical Chemistry</i> , 2018, 64, 830-842.	1.5	50
311	Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with <i>BRAF</i> V600 mutation-positive advanced cutaneous melanoma. <i>Journal of Dermatology</i> , 2018, 45, 397-407.	0.6	22
312	Combined BRAF and HSP90 Inhibition in Patients with Unresectable <i>BRAF</i> V600E-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5516-5524.	3.2	55
313	Concurrent BRAF/MEK Inhibitors in <i>BRAF</i> V600E-Mutant High-Grade Primary Brain Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 343-347.	2.3	46
314	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	7.7	393
315	BRAF-Targeted Therapy in the Treatment of BRAF-Mutant High-Grade Gliomas in Adults. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 451-454.	2.3	6
316	EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. <i>Cell Death and Disease</i> , 2018, 9, 269.	2.7	88
317	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	7.7	448
318	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123.	1.5	136
319	Cell death-based treatments of melanoma: conventional treatments and new therapeutic strategies. <i>Cell Death and Disease</i> , 2018, 9, 112.	2.7	94
320	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3
321	The role of nivolumab in melanoma. <i>Future Oncology</i> , 2018, 14, 1241-1252.	1.1	12
322	Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 529-541.	3.3	11
324	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. <i>Melanoma Research</i> , 2018, 28, 111-119.	0.6	51
325	Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 317-330.	1.5	22

#	ARTICLE	IF	CITATIONS
326	Development of encorafenib for BRAF-mutated advanced melanoma. <i>Current Opinion in Oncology</i> , 2018, 30, 125-133.	1.1	122
327	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	7.7	283
328	Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib. <i>JAAD Case Reports</i> , 2018, 4, 95-97.	0.4	4
329	Metastases to the parotid gland - A review of the clinicopathological evolution, molecular mechanisms and management. <i>Surgical Oncology</i> , 2018, 27, 44-53.	0.8	8
330	Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with <i>BRAF</i> V600 mutant tumours. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 764-775.	1.1	13
331	PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies. , 2018, , 321-331.		0
332	Update on adjuvant melanoma therapy. <i>Current Opinion in Oncology</i> , 2018, 30, 118-124.	1.1	12
333	Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With <i>BRAF</i> -Mutated High-Grade Glioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 4-10.	2.3	60
334	Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report. <i>Melanoma Research</i> , 2018, 28, 147-150.	0.6	5
335	Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 3-16.	1.9	81
336	State-of-the-Art Diagnosis and Treatment of Melanoma. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 331-339.	0.5	0
337	Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells. <i>Biology Open</i> , 2018, 7, .	0.6	5
338	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. <i>Cancer Treatment Reviews</i> , 2018, 66, 82-94.	3.4	112
339	Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661876761.	1.0	64
340	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	1.4	281
341	Treatment Sequencing in Advanced BRAF-Mutant Melanoma Patients: Current Practice in the United States. <i>Journal of Pharmacy Technology</i> , 2018, 34, 17-23.	0.5	5
342	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	5.1	732
343	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.	5.1	751

#	ARTICLE	IF	CITATIONS
344	Is there any interest in a new BRAF+MEK inhibitor combination in melanoma?. <i>Lancet Oncology</i> , The, 2018, 19, 580-581.	5.1	3
345	Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy. <i>JAAD Case Reports</i> , 2018, 4, 129-131.	0.4	0
346	Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. <i>Melanoma Research</i> , 2018, 28, 250-255.	0.6	17
347	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 90-94.	0.6	8
348	Combination therapy of BRAF inhibitors for advanced melanoma with <i>BRAF</i> V600 mutation: a systematic review and meta-analysis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 314-321.	1.1	11
349	A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 640-649.	1.2	6
350	The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 73-87.	1.0	32
351	Melanoma maligno con mutaci3n BRAF: terapia diana. <i>Piel</i> , 2018, 33, 295-299.	0.0	2
352	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 181-193.	3.3	18
353	Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 220-228.	1.4	59
354	Caspase inhibitors: a review of recently patented compounds (2013-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 47-59.	2.4	40
355	Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 151-167.	12.5	247
356	New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging. <i>Cancer Research</i> , 2018, 78, 542-557.	0.4	57
357	Acute intraventricular conduction disorder due to combination therapy with dabrafenib and trametinib for metastatic melanoma: Case report. <i>Journal of Dermatology</i> , 2018, 45, e120-e121.	0.6	1
358	MEK inhibitors under development for treatment of non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 17-30.	1.9	63
359	BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report. <i>Melanoma Research</i> , 2018, 28, 143-146.	0.6	4
360	Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2018, 56, 122-126.	0.3	6
361	Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 343-350.	1.4	26

#	ARTICLE	IF	CITATIONS
362	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , 2018, 31, 24-38.	2.9	324
363	The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases. <i>Pharmacological Research</i> , 2018, 135, 265-267.	3.1	6
364	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 303-317.	3.3	78
365	Leptomeningeal metastasis from systemic cancer: Review and update on management. <i>Cancer</i> , 2018, 124, 21-35.	2.0	175
366	Ceritinib Enhances the Efficacy of Trametinib in <i>BRAF/NRAS</i> -Wild-Type Melanoma Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 73-83.	1.9	18
367	Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	1.5	25
368	Toxicities with targeted therapies after immunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 600-604.	0.6	10
369	Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an <i>RAF1</i> Fusion. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	13
370	Conditional recurrence-free survival in patients with primary stage II cutaneous malignant melanoma – a population-based study. <i>Melanoma Research</i> , 2018, 28, 637-640.	0.6	3
371	Balancing RAF, MEK, and EGFR Inhibitor Doses to Achieve Clinical Responses and Modulate Toxicity in <i>BRAF</i> V600E Colorectal Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-4.	1.5	5
372	Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. <i>Oncotarget</i> , 2018, 9, 16110-16123.	0.8	25
373	New Era in the Management of Melanoma Brain Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 741-750.	1.8	52
374	Long-Term Outcomes in Patients With <i>BRAF</i> V600E Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	0.8	196
375	Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 759-762.	1.8	13
376	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1798-1804.	0.8	27
377	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600E Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
378	Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics. <i>Journal of Thoracic Disease</i> , 2018, 10, S4335-S4343.	0.6	5
379	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1

#	ARTICLE	IF	CITATIONS
381	Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 451-457.	0.6	13
382	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-19.	1.5	2
384	Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha. <i>Anticancer Research</i> , 2018, 38, 6393-6397.	0.5	3
385	Microneedle-Assisted Topical Delivery of Photodynamically Active Mesoporous Formulation for Combination Therapy of Deep-Seated Melanoma. <i>ACS Nano</i> , 2018, 12, 11936-11948.	7.3	121
386	Targeted Therapy of Melanoma. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2018, 19, S86.	0.8	0
387	Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. <i>PLoS ONE</i> , 2018, 13, e0206942.	1.1	35
388	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9081-9089.	1.0	41
389	Melanoma Cell Death Mechanisms. <i>Chonnam Medical Journal</i> , 2018, 54, 135.	0.5	29
390	A comprehensive review of protein kinase inhibitors for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1249-1270.	1.1	164
391	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
392	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. <i>BMJ Open</i> , 2018, 8, e017240.	0.8	20
393	A Novel Naphthyridine Derivative, 3u, Induces Necroptosis at Low Concentrations and Apoptosis at High Concentrations in Human Melanoma A375 Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2975.	1.8	22
394	A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2622-2632.	1.9	7
395	Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7095-7107.	1.0	187
396	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1625-1637.	0.5	10
397	Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 31-39.	3.3	208
398	Targeted Therapy in Advanced Melanoma. , 2018, , 1-20.		0
399	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1833-1844.	2.0	52

#	ARTICLE	IF	CITATIONS
400	Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1035-1040.	2.3	24
401	Translational Research and Genomics Driven Trials in Thyroid Cancer. , 2018, , 319-338.		0
402	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1315-1327.	5.1	469
403	Melanoma. Lancet, The, 2018, 392, 971-984.	6.3	1,016
404	Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 2018, 41, 343-349.	1.2	9
405	Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma. Cancer Research, 2018, 78, 5970-5979.	0.4	236
406	Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. Cancer Treatment Reviews, 2018, 70, 144-153.	3.4	27
407	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. European Journal of Cancer, 2018, 98, 10-16.	1.3	57
408	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. Melanoma Research, 2018, 28, 435-441.	0.6	9
409	Advances in the systemic treatment of melanoma brain metastases. Annals of Oncology, 2018, 29, 1509-1520.	0.6	31
410	Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy. Case Reports in Immunology, 2018, 2018, 1-8.	0.2	5
411	Cutaneous melanoma in adolescents and young adults. Pediatric Blood and Cancer, 2018, 65, e27292.	0.8	24
412	Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. , 2018, 192, 65-73.		35
413	Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. Expert Opinion on Biological Therapy, 2018, 18, 77-83.	1.4	13
414	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
416	Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. American Journal of Clinical Dermatology, 2018, 19, 639-646.	3.3	1
417	Cobimetinib (GDC-0973, XL518). Recent Results in Cancer Research, 2018, 211, 177-186.	1.8	9
418	Mechanisms and Therapy for Cancer Metastasis to the Brain. Frontiers in Oncology, 2018, 8, 161.	1.3	123



#	ARTICLE	IF	CITATIONS
419	Emerging targets in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 61-72.	1.1	21
420	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 140.	3.5	27
421	Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib+trametinib versus nivolumab or pembrolizumab monotherapy. <i>Current Medical Research and Opinion</i> , 2018, 34, 2169-2176.	0.9	5
422	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9
423	Effect of Age on Melanoma Risk, Prognosis and Treatment Response. <i>Acta Dermato-Venereologica</i> , 2018, 98, 624-629.	0.6	52
425	Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. <i>BMC Cancer</i> , 2018, 18, 490.	1.1	73
426	Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. <i>Molecular Cancer</i> , 2018, 17, 55.	7.9	75
428	The protective effect of some Thai plants and their bioactive compounds in UV light-induced skin carcinogenesis. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 185, 80-89.	1.7	9
429	Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review. <i>BMC Cancer</i> , 2018, 18, 549.	1.1	8
431	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 166-181.	0.9	10
432	Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1090.	1.8	34
433	Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 545-551.	0.5	6
434	BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. <i>Wspolczesna Onkologia</i> , 2018, 2018, 68-72.	0.7	38
435	Targeting MEK in a Translational Model of Histiocytic Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2439-2450.	1.9	24
436	Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF+MEK Inhibitors for Advanced Melanoma. <i>Dermatology</i> , 2018, 234, 92-98.	0.9	5
437	A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. <i>Cancer Letters</i> , 2018, 431, 171-181.	3.2	96
438	Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation. <i>Cell Chemical Biology</i> , 2018, 25, 996-1005.e4.	2.5	18
439	Sensitivity of different MRI sequences in the early detection of melanoma brain metastases. <i>PLoS ONE</i> , 2018, 13, e0193946.	1.1	27



#	ARTICLE	IF	CITATIONS
440	A Secondary Mutation in <i>BRAF</i> Confers Resistance to RAF Inhibition in a <i>BRAF</i> <sup>V600E</sup> -Mutant Brain Tumor. <i>Cancer Discovery</i> , 2018, 8, 1130-1141.	7.7	56
441	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2018, 140, 55-62.	1.4	25
442	Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. <i>Clinical Pharmacokinetics</i> , 2019, 58, 451-467.	1.6	72
443	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 389-397.	0.5	20
444	Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 461-473.	0.6	16
445	Targeted Therapy in Advanced Melanoma. , 2019, , 667-686.		0
446	Adjuvant Therapy. , 2019, , 717-741.		0
447	Side Effects of Systemic Therapy and Their Clinical Management. , 2019, , 773-789.		0
448	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
449	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 743-771.		0
450	Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review. <i>Cancer Medicine</i> , 2019, 8, 5414-5424.	1.3	14
451	Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e198890.	2.8	96
452	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> <sup>V600</sup> Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	31
453	Targeting Oncogenic BRAF: Past, Present, and Future. <i>Cancers</i> , 2019, 11, 1197.	1.7	143
454	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	1.3	75
455	Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques. <i>Bioorganic Chemistry</i> , 2019, 91, 103125.	2.0	9
456	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0
458	The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis. <i>Cancer</i> , 2019, 125, 3776-3789.	2.0	48

#	ARTICLE	IF	CITATIONS
459	A patent review of BRAF inhibitors: 2013-2018. Expert Opinion on Therapeutic Patents, 2019, 29, 595-603.	2.4	8
460	Copper chaperone ATOX1 is required for MAPK signaling and growth in <i>BRAF</i> mutation-positive melanoma. Metallomics, 2019, 11, 1430-1440.	1.0	39
461	Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathologica Communications, 2019, 7, 119.	2.4	47
462	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports, 2019, 21, 76.	1.8	18
463	&lt;p&gt;Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 5163-5175.	1.0	20
464	Metabolic flexibility in melanoma: A potential therapeutic target. Seminars in Cancer Biology, 2019, 59, 187-207.	4.3	62
465	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist, 2019, 24, e1197-e1211.	1.9	15
466	Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985649.	1.4	72
467	Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. Clinical Drug Investigation, 2019, 39, 1003-1007.	1.1	6
468	Basic principles of brain tumor chemotherapy. , 2019, , 309-330.		0
469	A large scale meta analysis identifies common adverse events with checkpoint inhibitors vs chemotherapy in melanoma patients. International Immunopharmacology, 2019, 74, 105691.	1.7	2
470	Molecular background of skin melanoma development and progression: therapeutic implications. Postepy Dermatologii I Alergologii, 2019, 36, 129-138.	0.4	22
471	Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers, 2019, 11, 845.	1.7	58
472	Targeted therapy for malignant melanoma. Current Opinion in Pharmacology, 2019, 46, 116-121.	1.7	19
473	Panniculitis Under Successful Targeted Inhibition of the MAPK/ERK Signaling Pathway in a Patient With BRAF V600E-mutated Spindle Cell Oncocytoma of the Pituitary Gland. Anticancer Research, 2019, 39, 3955-3959.	0.5	16
474	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Thyroid, 2019, 29, 1634-1645.	2.4	69
475	Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degradar. Journal of Medicinal Chemistry, 2019, 62, 10897-10911.	2.9	43
476	Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications, 2019, 10, 5167.	5.8	52

#	ARTICLE	IF	CITATIONS
477	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
478	Use of circulating tumoral DNA to guide treatment for metastatic melanoma. <i>Pharmacogenomics</i> , 2019, 20, 1259-1270.	0.6	6
479	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. <i>Cancers</i> , 2019, 11, 1642.	1.7	47
481	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. <i>Cancers</i> , 2019, 11, 1203.	1.7	10
482	The adjuvant treatment revolution for high-risk melanoma patients. <i>Seminars in Cancer Biology</i> , 2019, 59, 283-289.	4.3	40
483	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2019, 59, 290-297.	4.3	78
484	Elucidating value: the role of cost-effectiveness analysis in the decision-making process for the management of BRAF V600E/K mutation-positive melanoma. <i>Journal of Medical Economics</i> , 2019, 22, 1241-1242.	1.0	1
485	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
486	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2019, 37, 3142-3151.	0.8	83
487	Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. <i>Cancers</i> , 2019, 11, 1480.	1.7	31
488	Neo-DREAM study investigating Dabrafenib for the treatment of clinical stage IIIB/C melanoma. <i>Future Oncology</i> , 2019, 15, 3665-3674.	1.1	14
489	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 693-704.	1.1	21
490	MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF</i> -, <i>NRAS</i> -, and <i>NF1</i> -Mutant Melanomas. <i>Cancer Discovery</i> , 2019, 9, 526-545.	7.7	73
491	Patient preferences for treatment of metastatic melanoma. <i>Future Oncology</i> , 2019, 15, 1255-1268.	1.1	14
492	Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.	1.3	79
493	Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test. <i>Melanoma Research</i> , 2019, 29, 95-98.	0.6	6
494	Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival. <i>Future Oncology</i> , 2019, 15, 967-977.	1.1	10
495	Utility of Level III Axillary Node Dissection in Melanoma Patients with Palpable Axillary Lymph Node Disease. <i>Annals of Surgical Oncology</i> , 2019, 26, 2846-2854.	0.7	5

#	ARTICLE	IF	CITATIONS
496	Dynamics of neutrophil and C-reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib. <i>Journal of Dermatology</i> , 2019, 46, 716-719.	0.6	6
497	Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, , 216847901985599.	0.8	0
498	Adjuvant Therapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 63.	1.3	38
499	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	15.2	256
500	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. <i>Nature Medicine</i> , 2019, 25, 929-935.	15.2	188
501	Cost Utility of Target Therapies Compared to Dacarbazine for First-Line Treatment of Advanced Non-Surgical and Metastatic Melanoma in the Brazilian National Health System. <i>Value in Health Regional Issues</i> , 2019, 20, 103-109.	0.5	2
502	AKT and ERK dual inhibitors: The way forward?. <i>Cancer Letters</i> , 2019, 459, 30-40.	3.2	144
503	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 961-971.	5.1	126
504	Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. <i>PLoS ONE</i> , 2019, 14, e0217399.	1.1	12
505	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
506	Cells to Surgery Quiz: May 2019. <i>Journal of Investigative Dermatology</i> , 2019, 139, e53-e58.	0.3	0
507	Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 564-571.	1.8	42
508	Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. <i>Frontiers in Oncology</i> , 2019, 9, 268.	1.3	132
509	Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. <i>Neuro-Oncology</i> , 2019, 21, 1131-1140.	0.6	37
510	Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. <i>Journal of Medical Economics</i> , 2019, 22, 981-993.	1.0	20
511	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019, 46, 507-514.	0.6	9
512	MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance. <i>Nature Communications</i> , 2019, 10, 2030.	5.8	39
513	Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 232.	1.3	31

#	ARTICLE	IF	CITATIONS
514	HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. <i>Cancer Research</i> , 2019, 79, 2947-2961.	0.4	59
515	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2019, 120, 975-981.	2.9	61
516	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 1-29.		0
517	Redifferentiation of a <i>BRAF</i> <sup>K601E</sup> -Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment. <i>Thyroid</i> , 2019, 29, 735-742.	2.4	35
518	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3945-3952.	0.7	24
519	Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983082.	1.4	107
520	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup> -mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 3239-3246.	3.2	32
521	Patient-reported outcomes in patients with resected, high-risk melanoma with <i>BRAF</i> <sup>V600E</sup> or <i>BRAF</i> <sup>V600K</sup> mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50
522	Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of <i>BRAF</i> -mutant advanced melanoma: a matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2019, 11, 617-629.	1.0	29
523	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
524	Molecular genetics and therapeutic targets of pediatric low-grade gliomas. <i>Brain Tumor Pathology</i> , 2019, 36, 74-83.	1.1	19
525	Targeting the ERK Signaling Pathway in Melanoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1483.	1.8	116
526	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> <sup>V600E</sup> -Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	0.8	188
527	Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2019, 21, 21.	1.8	82
528	Network meta-analysis of therapies for previously untreated advanced <i>BRAF</i> -mutated melanoma. <i>Cancer Treatment Reviews</i> , 2019, 74, 43-48.	3.4	38
529	Sudden elevation of plasma D-dimer levels induced by the combination therapy of dabrafenib and trametinib: Report of two cases. <i>Journal of Dermatology</i> , 2019, 46, 358-360.	0.6	7
530	Interleukin-13 receptor $\beta_2$ is a novel marker and potential therapeutic target for human melanoma. <i>Scientific Reports</i> , 2019, 9, 1281.	1.6	33
531	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in <i>BRAF</i> <sup>V600E/K</sup> mutant advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 603-606.	1.5	18

#	ARTICLE	IF	CITATIONS
532	Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models. <i>Targeted Oncology</i> , 2019, 14, 223-235.	1.7	8
533	Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. <i>Future Oncology</i> , 2019, 15, 2933-2942.	1.1	32
534	Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management. <i>Seminars in Radiation Oncology</i> , 2019, 29, 166-170.	1.0	3
535	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478.	1.9	25
536	Adverse Event Management in Patients with <i>BRAF</i> V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. <i>Oncologist</i> , 2019, 24, 963-972.	1.9	16
537	Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?. <i>Oncologist</i> , 2019, 24, e1190-e1196.	1.9	24
538	Management of V600E and V600K <i>BRAF</i> -Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 81.	1.3	28
539	Trametinib in the treatment of multiple malignancies harboring <i>MEK1</i> mutations. <i>Cancer Treatment Reviews</i> , 2019, 81, 101907.	3.4	33
540	Systemic Therapy for Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 695-715.	0.6	9
541	Primary Melanoma: from History to Actual Debates. <i>Current Oncology Reports</i> , 2019, 21, 112.	1.8	8
542	OCULAR ADVERSE EVENTS ASSOCIATED WITH <i>MEK</i> INHIBITORS. <i>Retina</i> , 2019, 39, 1435-1450.	1.0	70
544	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. <i>Journal of Cancer</i> , 2019, 10, 6114-6123.	1.2	3
545	Fluvastatin exerts an antitumor effect in vemurafenib-resistant melanoma cells. <i>Anti-Cancer Drugs</i> , 2019, 30, 451-457.	0.7	5
546	Melanoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 543-553.	0.7	1
547	Clinical experience with combination <i>BRAF/MEK</i> inhibitors for melanoma with brain metastases: a real-life multicenter study. <i>Melanoma Research</i> , 2019, 29, 65-69.	0.6	27
548	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
549	Effectiveness of dabrafenib in the treatment of patients with <i>BRAF</i> V600E-mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	0.6	6
550	Severe gastrointestinal toxicity of <i>MEK</i> inhibitors. <i>Melanoma Research</i> , 2019, 29, 556-559.	0.6	13

#	ARTICLE	IF	CITATIONS
551	Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit. <i>International Ophthalmology Clinics</i> , 2019, 59, 13-26.	0.3	9
552	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 245-253.	1.0	4
553	Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency. <i>Melanoma Research</i> , 2019, 29, 99-101.	0.6	7
554	Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damage. <i>Melanoma Research</i> , 2019, 29, 134-144.	0.6	12
555	B-RAFV600E Inhibitor Dabrafenib Attenuates RIPK3-Mediated Necroptosis and Promotes Functional Recovery after Spinal Cord Injury. <i>Cells</i> , 2019, 8, 1582.	1.8	13
556	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	1.3	13
557	CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 149-159.	1.9	21
558	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. <i>Immunotherapy</i> , 2019, 11, 283-295.	1.0	24
559	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	1.3	31
560	Indications for the surgical resection of stage IV disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 249-261.	0.8	14
561	Rational combination of cancer immunotherapy in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 433-447.	1.4	7
562	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111.	2.0	48
563	Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores. <i>Gynecologic Oncology</i> , 2019, 152, 106-111.	0.6	31
564	Management of in-transit melanoma metastases: a review. <i>ANZ Journal of Surgery</i> , 2019, 89, 647-652.	0.3	18
565	A Survey of the Structures of US FDA Approved Combination Drugs. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4265-4311.	2.9	164
566	Nivolumab to pembrolizumab switch induced a durable melanoma response. <i>Medicine (United States)</i> , 2019, 98, e13804.	0.4	14
567	Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. <i>Immunotherapy</i> , 2019, 11, 297-309.	1.0	22
568	IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis. <i>Pancreas</i> , 2019, 48, 94-98.	0.5	6



#	ARTICLE	IF	CITATIONS
569	Comparative and combined effectiveness of innovative therapies in cancer: a literature review. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 205-216.	0.6	3
570	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 259-266.	1.3	44
571	Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer. <i>EBioMedicine</i> , 2019, 40, 305-317.	2.7	21
572	Hyponatremia and MAPK kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 326-331.	1.5	5
573	The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 33-49.	3.0	59
575	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. <i>Cancer</i> , 2019, 125, 884-891.	2.0	43
576	The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis. <i>Cutaneous and Ocular Toxicology</i> , 2019, 38, 105-111.	0.5	5
577	Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 11-17.	1.1	6
578	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 278-288.	1.9	24
579	Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. <i>Future Oncology</i> , 2019, 15, 459-471.	1.1	27
580	Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction. <i>Platelets</i> , 2019, 30, 762-772.	1.1	7
581	Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. <i>Pathology and Oncology Research</i> , 2019, 25, 45-50.	0.9	9
582	Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1508-1514.	1.0	13
584	Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 74-85.	1.5	8
585	Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 86-95.	1.5	11
586	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
587	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	0.5	40
588	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. <i>Cancer</i> , 2020, 126, 523-530.	2.0	43



#	ARTICLE	IF	CITATIONS
589	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 390-402.	1.5	19
590	Mitogen-activated protein kinase dependency in <i>BRAF</i> / <i>RAS</i> wild-type melanoma: A rationale for combination inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 345-357.	1.5	2
591	Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas. <i>Oncologist</i> , 2020, 25, e291-e301.	1.9	13
592	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600 mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	1.3	130
593	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020, 126, 1166-1174.	2.0	32
594	Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 234-243.e10.	0.2	0
595	Genomics and the History of Precision Oncology. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 35-49.	0.6	23
596	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2020, 13, 275-286.	1.7	13
597	The "ART" of Epigenetics in Melanoma: From histone Alterations, to Resistance and Therapies. <i>Theranostics</i> , 2020, 10, 1777-1797.	4.6	44
598	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , 2020, 30, 261-267.	0.6	27
600	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	1.1	6
601	Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy. <i>Melanoma Research</i> , 2020, 30, 213-218.	0.6	4
602	New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 206-208.	0.6	0
603	Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. <i>British Journal of Cancer</i> , 2020, 122, 506-516.	2.9	16
604	Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma. <i>Current Opinion in Oncology</i> , 2020, 32, 91-97.	1.1	7
605	The clinical characteristics of melanoma with BRAF V600R mutation: a case series study. <i>Melanoma Research</i> , 2020, 30, 107-112.	0.6	6
606	Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 285-295.	3.3	60
607	BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 321-326.	0.9	6

#	ARTICLE	IF	CITATIONS
608	Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, 257-264.	0.6	10
609	Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 85-90.	1.1	8
610	Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. <i>Journal of Oncology</i> , 2020, 2020, 1-14.	0.6	14
611	Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 1748.	1.3	9
612	Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. <i>Cancers</i> , 2020, 12, 2801.	1.7	73
614	Predicting the clinical outcome of melanoma using an immune-related gene pairs signature. <i>PLoS ONE</i> , 2020, 15, e0240331.	1.1	9
615	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020, 38, 3883-3894.	0.8	168
616	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 1569-1579.	0.6	18
618	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. <i>European Journal of Cancer</i> , 2020, 138, 68-76.	1.3	10
619	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. <i>Nature Medicine</i> , 2020, 26, 1564-1568.	15.2	71
620	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. <i>Gastroenterology Report</i> , 2020, 8, 192-205.	0.6	59
621	Next Generation Kinase Inhibitors. , 2020, , .		8
622	Melanoma brain metastases – Interdisciplinary management recommendations 2020. <i>Cancer Treatment Reviews</i> , 2020, 89, 102083.	3.4	52
623	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAFV600E/K</i>-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	3.2	23
624	Rapid BRAF Mutation Testing in Pigmented Melanomas. <i>American Journal of Dermatopathology</i> , 2020, 42, 343-348.	0.3	7
625	Targeted and immunotherapies in <i>BRAF</i> mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021, 185, 253-262.	1.4	20
626	Ras Pathways on Prox1 and Lymphangiogenesis: Insights for Therapeutics. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 597374.	1.1	23
627	Advances in Targeted Therapies for Pediatric Brain Tumors. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	0.7	16

#	ARTICLE	IF	CITATIONS
628	Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups. BMC Medical Genomics, 2020, 13, 179.	0.7	3
629	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications, 2020, 11, 6262.	5.8	50
630	Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature, 2020, 588, 509-514.	13.7	86
631	Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study. European Journal of Cancer, 2020, 137, 127-135.	1.3	14
632	Current State of Target Treatment in BRAF Mutated Melanoma. Frontiers in Molecular Biosciences, 2020, 7, 154.	1.6	82
633	Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation. International Journal of Clinical Oncology, 2020, 25, 1870-1878.	1.0	7
634	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. Cancers, 2020, 12, 1994.	1.7	26
635	Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy. Case Reports in Oncological Medicine, 2020, 1-6.	0.2	3
636	A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Frontiers in Pharmacology, 2020, 11, 891.	1.6	48
637	Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer, 2020, 6, 797-810.	3.8	169
638	New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction. Life Sciences, 2020, 257, 118123.	2.0	12
639	Advances in the Systemic Treatment of Melanoma Brain Metastases. , 2020, , .		0
641	Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Molecular Cancer Therapeutics, 2020, 19, 2308-2318.	1.9	14
642	Identification of New Therapeutic Targets for Gastric Cancer With Bioinformatics. Frontiers in Genetics, 2020, 11, 865.	1.1	10
643	Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. Melanoma Research, 2020, 30, 477-483.	0.6	5
645	B-Raf-Mutated Melanoma. , 2020, , .		0
646	Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncology, The, 2020, 21, 1234-1243.	5.1	297
647	Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations. Clinical Lung Cancer, 2021, 22, e668-e672.	1.1	4

#	ARTICLE	IF	CITATIONS
648	Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9730.	1.8	15
649	Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy. <i>Dermatologic Therapy</i> , 2020, 33, e14430.	0.8	2
650	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. <i>Scientific Reports</i> , 2020, 10, 18878.	1.6	16
651	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571135.	1.3	2
652	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. <i>Karger Kompass Dermatologie</i> , 2020, 8, 92-101.	0.0	0
653	Small molecules—Giant leaps for immuno-oncology. <i>Progress in Medicinal Chemistry</i> , 2020, 59, 1-62.	4.1	2
654	An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. <i>Clinical Drug Investigation</i> , 2020, 40, 629-643.	1.1	13
655	Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain. <i>Translational Oncology</i> , 2020, 13, 100750.	1.7	5
656	CARs: Beyond T Cells and T Cell-Derived Signaling Domains. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3525.	1.8	19
657	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
658	BRAF mutation and its inhibitors in sarcoma treatment. <i>Cancer Medicine</i> , 2020, 9, 4881-4896.	1.3	26
659	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
660	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 135, 31-38.	1.3	11
661	Correlation of novel ALK ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. <i>Histopathology</i> , 2020, 77, 601-610.	1.6	5
662	Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model. <i>Cancer Cell International</i> , 2020, 20, 253.	1.8	17
663	Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. <i>Targeted Oncology</i> , 2020, 15, 407-410.	1.7	17
664	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. <i>Cancers</i> , 2020, 12, 1519.	1.7	15
665	The Potential of Tumor Debulking to Support Molecular Targeted Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 801.	1.3	6

#	ARTICLE	IF	CITATIONS
666	Viral Vector-Based Melanoma Gene Therapy. <i>Biomedicines</i> , 2020, 8, 60.	1.4	16
667	Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. <i>Biomedicines</i> , 2020, 8, 61.	1.4	36
668	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	8
669	Risk factors for the development of a second melanoma in patients with cutaneous melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2295-2302.	1.3	18
670	Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 493-504.	3.3	30
671	MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4544.	1.8	24
672	Melanoma Brain Metastases in the Era of Target Therapies: An Overview. <i>Cancers</i> , 2020, 12, 1640.	1.7	29
673	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	1.7	17
674	BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. <i>Cancers</i> , 2020, 12, 1823.	1.7	82
675	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
676	Redifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. <i>Cancer Treatment Reviews</i> , 2020, 88, 102060.	3.4	27
677	Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma. <i>Cancer Research</i> , 2020, 80, 1387-1400.	0.4	29
678	Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma. <i>Neurology</i> , 2020, 94, 322-323.	1.5	8
679	<i>BRAF</i> -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2466-2476.	3.2	39
680	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> , 2020, 12, 512.	1.7	15
681	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 46-53.	3.2	32
682	Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors. <i>Clinical and Translational Oncology</i> , 2020, 22, 1818-1824.	1.2	7
683	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885.	3.0	20

#	ARTICLE	IF	CITATIONS
684	miRNAs as Key Players in the Management of Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 415.	1.8	23
685	Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis. <i>Cancer Medicine</i> , 2020, 9, 2611-2620.	1.3	16
686	Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 223.	1.0	95
687	Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy. <i>Targeted Oncology</i> , 2020, 15, 101-113.	1.7	18
688	Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 528-533.	0.8	0
689	An ultrasensitive colorimetric test for the detection of somatic rare mutations in DNA. <i>Nanoscale</i> , 2020, 12, 2973-2979.	2.8	6
690	Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma. <i>JCO Precision Oncology</i> , 2020, 4, 44-50.	1.5	18
691	Current Treatment of Melanoma Brain Metastasis. <i>Current Treatment Options in Oncology</i> , 2020, 21, 45.	1.3	23
692	Adult Craniopharyngiomas. , 2020, , .		3
693	Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 917-930.	1.1	29
694	BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004820.	0.5	4
695	Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer. <i>FEBS Open Bio</i> , 2020, 10, 1149-1161.	1.0	10
697	An alternative pathway for cellular protection in BRAF inhibitor resistance in aggressive melanoma type skin cancer. <i>Chemico-Biological Interactions</i> , 2020, 323, 109061.	1.7	6
698	Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. <i>Journal of Dermatology</i> , 2020, 47, 654-657.	0.6	5
699	Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2261-2267.	1.3	6
700	ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 325-336.	1.9	66
701	A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2020, 25, 833-e1438.	1.9	21
702	Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	3.2	17

#	ARTICLE	IF	CITATIONS
703	Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1754-1758.	0.5	2
704	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	0.8	190
705	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2367.	1.8	34
706	Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics - Open</i> , 2021, 5, 13-22.	0.9	5
707	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
709	Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1554-1561.	0.6	15
710	Current Management of Melanoma. <i>Updates in Surgery Series</i> , 2021, , .	0.0	0
711	Recent advances in the management of cutaneous malignant melanoma: our case cohort. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2021, 59, 534-545.	0.4	5
712	Surgery of metastatic melanoma after systemic therapy – the SUMMIST trial: study protocol for a randomized controlled trial. <i>Acta Oncologica</i> , 2021, 60, 52-55.	0.8	5
713	Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 205-206.	0.5	0
714	Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. <i>Journal of Dermatology</i> , 2021, 48, 397-400.	0.6	7
715	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27.	0.9	4
716	Brain metastases in metastatic cancer: a review of recent advances in systemic therapies. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 325-339.	1.1	10
717	BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series. <i>Skeletal Radiology</i> , 2021, 50, 1257-1262.	1.2	3
718	Where are adolescents with cutaneous melanoma treated? An Italian nationwide study on referrals based on hospital discharge records. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28566.	0.8	2
719	Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. <i>Thoracic Cancer</i> , 2021, 12, 272-276.	0.8	3
720	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
721	Chimeric antigen receptor T-cell therapy for melanoma. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 209-223.	1.3	12



#	ARTICLE	IF	CITATIONS
722	Practical Management of Melanoma. , 2021, , 241-256.		0
723	Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma. Journal of Dermatology, 2021, 48, e135-e136.	0.6	1
724	Vemurafenib and Cobimetinib. , 2021, , 149-165.		0
725	Systemic Implications of Melanoma. , 2021, , 91-115.		1
726	Dabrafenib and Trametinib. , 2021, , 131-147.		0
727	New Therapies in Advanced Cutaneous Malignancies: Conclusions. , 2021, , 441-448.		1
728	Melanoom en andere huidtumoren. , 2021, , 515-526.		0
729	Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management. World Journal of Oncology, 2021, 12, 7-19.	0.6	53
730	Obstructive Jaundice Secondary to Pancreatic Head Metastasis of Malignant Amelanotic Melanoma as the First Clinical Manifestation. Prague Medical Report, 2021, 122, 45-51.	0.4	2
731	Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermo-sifiliogrÁficas, 2021, 112, 142-152.	0.2	2
732	Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. European Journal of Cancer, 2021, 144, 242-251.	1.3	16
733	Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2731-2740.	1.2	3
734	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1365-1378.	1.2	2
735	Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina. Oncology and Therapy, 2021, 9, 167-185.	1.0	3
736	Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth <i>in vitro</i> and <i>in vivo</i> . Molecular Carcinogenesis, 2021, 60, 201-212.	1.3	15
737	The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. Journal of Clinical Medicine, 2021, 10, 566.	1.0	21
738	Defining and Targeting BRAF Mutations in Solid Tumors. Current Treatment Options in Oncology, 2021, 22, 30.	1.3	25
739	Melanoma of unknown primary: New perspectives for an old story. Critical Reviews in Oncology/Hematology, 2021, 158, 103208.	2.0	37



#	ARTICLE	IF	CITATIONS
740	Role of transforming growth factor- $\alpha$ 21 in recessive dystrophic epidermolysis bullosa squamous cell carcinoma. <i>Experimental Dermatology</i> , 2021, 30, 664-675.	1.4	5
741	Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment. <i>Cancers</i> , 2021, 13, 758.	1.7	20
742	Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. <i>European Journal of Cancer</i> , 2021, 145, 210-220.	1.3	27
743	An Update on the Role of Ubiquitination in Melanoma Development and Therapies. <i>Journal of Clinical Medicine</i> , 2021, 10, 1133.	1.0	7
744	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 881-889.	0.8	37
745	Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. <i>Nature Communications</i> , 2021, 12, 1747.	5.8	39
746	BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients. <i>Melanoma Research</i> , 2021, 31, 218-223.	0.6	4
747	Targeting Genome Stability in Melanoma—A New Approach to an Old Field. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3485.	1.8	4
748	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
749	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. <i>Cancers</i> , 2021, 13, 1430.	1.7	50
750	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
751	VarÃ³n de 57 aÃ±os con lesiÃ³n interdigital en el pie izquierdo. <i>Medicine</i> , 2021, 13, 1546.e1-1546.e4.	0.0	0
752	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 79-92.	1.0	13
753	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	3.3	18
755	First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?. <i>JMIR Cancer</i> , 2021, 7, e29912.	0.9	4
756	Targeting pan-essential genes in cancer: Challenges and opportunities. <i>Cancer Cell</i> , 2021, 39, 466-479.	7.7	88
757	Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. <i>Trials</i> , 2021, 22, 294.	0.7	1
758	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0

#	ARTICLE	IF	CITATIONS
759	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , 2021, 11, 9043.	1.6	13
760	Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 2373-2379.	0.3	0
761	Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines. <i>BMC Genomics</i> , 2021, 22, 272.	1.2	25
762	Bone Morphogenic Protein Signaling and Melanoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 48.	1.3	4
763	Pulmonary metastasectomy in the era of targeted therapy and immunotherapy. <i>Journal of Thoracic Disease</i> , 2021, 13, 2618-2627.	0.6	12
764	Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1371-1379.	0.9	0
765	Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. <i>Cancers</i> , 2021, 13, 2282.	1.7	6
766	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	3.3	6
767	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	13.7	64
768	Dramatic response to encorafenib in a patient with <sup>E</sup>rdheimâ€™ <sup>C</sup>hester disease harboring the <sup>BRAF</sup>V600E<sup>/sup> mutation. <i>American Journal of Hematology</i> , 2021, 96, E295-E298.	2.0	1
769	Phase II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <sup>BRAF</sup>V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. <i>Clinical Cancer Research</i> , 2021, 27, 3876-3883.	3.2	8
770	Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. <i>Cancer Medicine</i> , 2021, 10, 3155-3164.	1.3	5
771	Discovery of New Imidazo[2,1- <i>b</i> ]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising <sup>In Vitro</sup> and <sup>In Vivo</sup> Anti-melanoma Activity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6877-6901.	2.9	15
772	The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and â€œBrainstormingâ€™ Session. , 0, , .		2
773	Retinal toxicities of systemic anticancer drugs. <i>Survey of Ophthalmology</i> , 2022, 67, 97-148.	1.7	16
774	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
775	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	0.8	7
776	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. <i>European Journal of Cancer</i> , 2021, 149, 211-221.	1.3	9

#	ARTICLE	IF	CITATIONS
777	RAF-MEK-ERK pathway in cancer evolution and treatment. <i>Seminars in Cancer Biology</i> , 2022, 85, 123-154.	4.3	113
778	The Combination of Trametinib, a MEK Inhibitor, and Temezirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells. <i>Anticancer Research</i> , 2021, 41, 2885-2894.	0.5	4
779	Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?. <i>Medicine (United States)</i> , 2021, 100, e26388.	0.4	8
780	Re-thinking therapeutic development for CNS metastatic disease. <i>Experimental Dermatology</i> , 2021, , .	1.4	1
781	Large-scale literature mining to assess the relation between anti-cancer drugs and cancer types. <i>Journal of Translational Medicine</i> , 2021, 19, 274.	1.8	4
782	Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 3042.	1.7	3
783	The role of immunotherapy and molecular-targeted therapy in the treatment of melanoma (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	14
784	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
785	Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. <i>Future Oncology</i> , 2021, 17, 2151-2167.	1.1	4
786	BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma. <i>Melanoma Management</i> , 2021, 8, MMT55.	0.1	2
787	First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. <i>Cancer Reports</i> , 2021, 4, e1419.	0.6	4
788	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 670726.	1.3	26
789	Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600 melanoma patients. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 32-38.	0.5	4
790	Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103353.	2.0	8
791	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
792	Prognostic Value of an Immunohistochemical Signature in Patients With Head and Neck Mucosal Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 708293.	2.2	1
793	The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis. <i>Oncogene</i> , 2021, 40, 5286-5301.	2.6	9
794	Histiocytosis. <i>Lancet, The</i> , 2021, 398, 157-170.	6.3	58

#	ARTICLE	IF	CITATIONS
795	Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments. <i>Melanoma Management</i> , 2021, 8, MMT58.	0.1	7
796	MEK inhibition by trametinib overcomes chemoresistance in preclinical nasopharyngeal carcinoma models. <i>Anti-Cancer Drugs</i> , 2021, 32, 978-985.	0.7	6
797	Treatment of Advanced Metastatic Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021164S.	0.5	10
798	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
799	Aloysia Citroedora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8151.	1.8	7
800	Precision oncology: a clinical and patient perspective. <i>Future Oncology</i> , 2021, 17, 3995-4009.	1.1	22
801	Expedition of sulfur-containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update. <i>Medicinal Research Reviews</i> , 2022, 42, 513-575.	5.0	33
802	Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review. <i>Melanoma Research</i> , 2021, 31, 413-420.	0.6	5
803	Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2021, 154, 197-203.	1.4	10
804	Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments. , 2021, 224, 107829.		12
805	Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2049-2060.	1.9	16
806	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2022, 17, 103-115.	0.5	89
807	Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib. <i>Cureus</i> , 2021, 13, e17488.	0.2	4
808	Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1297-1305.	0.4	6
809	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	0.8	21
810	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1031-1038.	0.5	2
811	BRAF mutation correlates with worse local/regional control following radiation therapy in patients with stage III melanoma. <i>Radiation Oncology</i> , 2021, 16, 181.	1.2	5
812	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage Tj ETQq1 1 0.784314 rgBT /Over IIIb study of trametinib in combination with dabrafenib. <i>European Journal of Cancer</i> , 2021, 154, 57-65.	1.3	9

#	ARTICLE	IF	CITATIONS
813	Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 741993.	1.3	9
814	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 349-360.	0.4	0
815	Gibt es eine Äœberbehandlung von Melanompatienten am Ende ihres Lebens? Ergebnisse einer multizentrischen Studie an 193 Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1297-1306.	0.4	0
816	Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: analysis of 36 cases. <i>Melanoma Research</i> , 2021, 31, 575-578.	0.6	5
817	Molecular Markers and Targets in Melanoma. <i>Cells</i> , 2021, 10, 2320.	1.8	72
818	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	0.5	4
819	Ipilimumab in a realâ€world population: A prospective Phase <scp>IV</scp> trial with longâ€term followâ€up. <i>International Journal of Cancer</i> , 2022, 150, 100-111.	2.3	11
820	Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29346.	0.8	1
821	Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1047-1056.	1.9	4
822	Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy. <i>Cancers</i> , 2021, 13, 4493.	1.7	2
823	Dermatologic adverse events associated with targeted therapies for melanoma. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 385-395.	1.0	0
824	Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma. , 2021, , 161-202.		2
825	Inherited Gene Mutations in Melanoma. , 2016, , 117-149.		1
826	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 767-793.		1
827	The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. <i>Recent Results in Cancer Research</i> , 2020, 214, 169-187.	1.8	7
829	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 51-68.	0.8	41
830	Avoiding or Co-Opting ATP Inhibition: Overview of Type III, IV, V, and VI Kinase Inhibitors. , 2020, , 29-59.		9
831	Title is missing!. , 2017, , .		82

#	ARTICLE	IF	CITATIONS
832	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
833	Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells. ACS Applied Bio Materials, 2020, 3, 8481-8495.	2.3	4
834	Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. Acta Oncol <sup>3</sup> gica, 2020, 59, 438-443.	0.8	7
835	Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany. Journal of Market Access & Health Policy, 2021, 9, 1861804.	0.8	5
836	Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience. Journal of Pediatric Hematology/Oncology, 2020, 42, e730-e737.	0.3	13
837	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2019, 32, 458-469.	1.5	31
839	Cancer Genomics. F1000Research, 2015, 4, 1162.	0.8	2
840	Radiation recall dermatitis with dabrafenib and trametinib: A case report. World Journal of Clinical Cases, 2020, 8, 522-526.	0.3	5
841	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Oncotarget, 2018, 9, 12408-12417.	0.8	11
842	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. Oncotarget, 2016, 7, 56619-56627.	0.8	16
843	c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus. Oncotarget, 2016, 7, 53869-53880.	0.8	17
844	Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget, 2016, 7, 68314-68327.	0.8	56
845	Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 32258-32269.	0.8	37
846	Molecular dissection of effector mechanisms of <i>RAS</i> -mediated resistance to anti-EGFR antibody therapy. Oncotarget, 2017, 8, 45898-45917.	0.8	12
847	NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget, 2017, 8, 45687-45697.	0.8	7
848	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	0.8	21
849	Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget, 2017, 8, 55715-55730.	0.8	76
850	Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget, 2017, 8, 83280-83291.	0.8	36

#	ARTICLE	IF	CITATIONS
851	New role of ID3 in melanoma adaptive drug-resistance. <i>Oncotarget</i> , 2017, 8, 110166-110175.	0.8	20
852	Methotrexate sensitizes drug-resistant metastatic melanoma cells to <i>BRAF</i> V600E inhibitors dabrafenib and encorafenib. <i>Oncotarget</i> , 2018, 9, 13324-13336.	0.8	6
853	A new B-Raf inhibitor combo for advanced melanoma. <i>Oncotarget</i> , 2018, 9, 34457-34458.	0.8	2
854	A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors. <i>Oncotarget</i> , 2019, 10, 1669-1687.	0.8	12
855	Plasma lncRNA expression profile as a prognostic tool in <i>BRAF</i> -mutant metastatic melanoma patients treated with BRAF inhibitor. <i>Oncotarget</i> , 2019, 10, 3879-3893.	0.8	16
856	Colorectal cancer genomics and designing rational trials. <i>Annals of Translational Medicine</i> , 2018, 6, 159-159.	0.7	19
857	Progress in Research on Tumor Metastasis Inhibitors. <i>Current Medicinal Chemistry</i> , 2020, 27, 5758-5772.	1.2	1
858	Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 2792-2813.	1.2	12
859	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
860	Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1415-1430.	0.9	3
861	Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2017, 5, e101.	1.8	29
862	Biological therapy in the treatment of melanoma. <i>Journal of Mind and Medical Sciences</i> , 2018, 5, 169-175.	0.1	2
863	FGFR3-TACC3: A novel gene fusion in malignant melanoma. <i>Precision and Future Medicine</i> , 2018, 2, 71-75.	0.5	7
864	Melanome : effets indésirables des traitements innovants. <i>Oncologie</i> , 2018, 20, 11-17.	0.2	2
865	The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. <i>Cancers</i> , 2015, 7, 1154-1177.	1.7	20
866	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e94.	1.0	29
867	Extracranial systemic antitumor response through the abscopal effect induced by brain radiation in a patient with metastatic melanoma. <i>Radiation Oncology Journal</i> , 2019, 37, 302-308.	0.7	11
868	Multiple primary melanomas: Our experience. <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 88.	0.8	7





#	ARTICLE	IF	CITATIONS
887	Malignes Melanom beim alten und geriatrischen Patienten. , 2017, , 1-8.		0
888	New Approaches to Signaling. , 2017, , 399-425.		0
890	BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma. OnCOReview, 2017, 7, 139-143.	0.1	0
891	Adjuvant Therapy. , 2018, , 1-25.		0
892	Side Effects of Systemic Therapy and Their Clinical Management. , 2018, , 1-17.		0
893	Malignes Melanom beim alten und geriatrischen Patienten. , 2018, , 527-534.		0
894	Melanome : actualités physiopathologiques et stratégies thérapeutiques. Oncologie, 2018, 20, 3-10.	0.2	1
897	Analysis of Advanced Melanomas Changed from Immune Checkpoint Blockade Therapy to Palliative Care. Nishinon Journal of Dermatology, 2018, 80, 51-55.	0.0	0
898	Malignes Melanom: Optionen für Patienten im fortgeschrittenen Stadium. Deutsches Ärzteblatt International, 0, , .	0.6	0
899	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2019, , 1-19.		0
900	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-27.		0
901	A durable complete response to pembrolizumab therapy in a female patient with metastatic melanoma involving the bones. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 221.	0.0	0
902	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
903	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0
904	Melanom. , 2019, , 45-134.		0
905	Targeted and Immune Therapy for Periocular and Orbital Malignancies. Current Practices in Ophthalmology, 2019, , 83-97.	0.1	0
908	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
909	Malignancy, Staging and Surgical Management. , 2020, , 77-104.		0

#	ARTICLE	IF	CITATIONS
910	Management of Melanoma Brain Metastasis. , 2020, , 281-287.		0
911	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 203-225.	0.8	1
913	Role of Precision Medicine in Patients with CNS Metastasis. , 2020, , 69-82.		0
914	Survival in melanoma brain metastases in the era of novel systemic therapies. Neuro-Oncology Advances, 2020, 2, vdaa144.	0.4	2
916	Jaundice and Haematemesis: An Unusual Presentation of Metastatic Malignant Melanoma. Cureus, 2020, 12, e8035.	0.2	2
917	BRAF Mutant Metastatik Melanomda Dabrafenib-trametinib Kombinasyon Tedavisi SonrasÄ± GeliÅŸen Yan Etki YÄ°netimi: Å°ki Olgu Sunumuyla Birlikte LiteratÅ¼r Derlemesi. OsmangazÅ° Journal of Medicine, 0, , .	0.1	0
918	Current prospects of successful therapeutic procedures in advanced stage melanoma â€” the short review. Journal of Education, Health and Sport, 2020, 10, 308.	0.0	0
919	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. Journal of Clinical Medicine, 2021, 10, 4994.	1.0	4
920	MAPK blockade, toxicities, pathogenesis and management. Current Opinion in Oncology, 2021, 33, 139-145.	1.1	3
921	Modern combined targeted and immunotherapy of metastatic skin melanoma. Meditsinskiy Sovet, 2020, , 54-61.	0.1	1
922	Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrology Dialysis Transplantation, 2022, 37, 507-514.	0.4	10
923	Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma. Japanese Journal of Clinical Oncology, 2021, 51, 315-320.	0.6	2
924	Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1590-1595.	2.3	15
925	Development of heart failure upon dabrafenib and trametinib administration in malignant melanoma : case report. Skin Cancer, 2021, 36, 149-152.	0.1	0
926	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
927	Leptomeningeal Disease and the Role of Intrathecal Therapy. , 2020, , 169-186.		1
928	Molecular Targets in Craniopharyngioma. , 2020, , 209-221.		1
929	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2020, , 1067-1085.		0

#	ARTICLE	IF	CITATIONS
930	A Case of Emergency Laparoscopic Surgery for Intestinal Intussusception and Obstruction due to Jejunal Metastasis of Malignant Melanoma. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2020, 73, 121-126.	0.1	1
931	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
932	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?. <i>Frontiers in Oncology</i> , 2021, 11, 775100.	1.3	6
933	Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients. <i>Current Oncology Reports</i> , 2021, 23, 138.	1.8	11
934	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. <i>Frontiers in Oncology</i> , 2021, 11, 772052.	1.3	18
936	The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 182-189.	0.5	8
938	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66.	0.6	6
939	Targeted drug combinations: avant-garde oncology. <i>Annals of Translational Medicine</i> , 2015, 3, 159.	0.7	0
940	Raising the bar: optimizing combinations of targeted therapy and immunotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, 272.	0.7	0
941	Tyrosine-kinase Inhibitors Treatment in Advanced Malignant Melanoma. <i>MÃ  dica</i> , 2017, 12, 293-296.	0.4	2
945	Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 73.	0.4	2
946	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. <i>Translational Oncology</i> , 2022, 15, 101290.	1.7	4
947	Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. <i>Nature Communications</i> , 2021, 12, 7008.	5.8	22
948	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7
949	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. <i>Oncologist</i> , 2022, 27, e463-e470.	1.9	7
950	Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. , 0, , .		0
951	Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	0
952	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115

#	ARTICLE	IF	CITATIONS
953	Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors. <i>Health Economics Review</i> , 2022, 12, 8.	0.8	1
954	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
955	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 785526.	2.2	6
957	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 328-332.	0.5	4
958	Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma cfDNA, LDH, VEGF, PD-L1, and IFN- $\gamma$ Measurements. <i>Anticancer Research</i> , 2022, 42, 801-810.	0.5	0
959	Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism. <i>Pharmaceutics</i> , 2022, 14, 310.	2.0	1
960	Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. <i>Journal of Biological Chemistry</i> , 2022, 298, 101525.	1.6	9
961	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	3.4	21
962	Mechanisms of immune activation and regulation: lessons from melanoma. <i>Nature Reviews Cancer</i> , 2022, 22, 195-207.	12.8	101
963	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
964	Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice. <i>Radiotherapy and Oncology</i> , 2022, 168, 89-94.	0.3	4
965	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 51.	3.5	9
966	Prediction of Drug-Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 353-361.	0.6	3
967	How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. <i>Blood</i> , 2022, 139, 2294-2305.	0.6	9
968	Reliability of BRAF mutation detection using plasma sample. <i>Medicine (United States)</i> , 2021, 100, e28382.	0.4	4
969	Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies. <i>Antioxidants</i> , 2021, 10, 1942.	2.2	33
971	Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	0.8	2
973	MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumorigenesis. <i>Cancers</i> , 2022, 14, 1378.	1.7	4

#	ARTICLE	IF	CITATIONS
974	Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. <i>Oncogene</i> , 2022, 41, 2571-2586.	2.6	6
975	STARBOARD: encorafenib+binimetinib+ pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. <i>Future Oncology</i> , 2022, 18, 2041-2051.	1.1	9
976	Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts. <i>Biomedicines</i> , 2022, 10, 717.	1.4	3
977	SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 703-711.	1.2	2
978	NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation. <i>Cancers</i> , 2022, 14, 1531.	1.7	17
979	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma. <i>Clinical Cancer Research</i> , 2022, 28, 2425-2439.	3.2	17
980	The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K/Akt Pathways. <i>Pharmaceutics</i> , 2022, 14, 590.	2.0	11
981	Targeted Therapy for Melanomas Without BRAF V600 Mutations. <i>Current Treatment Options in Oncology</i> , 2022, 23, 831-842.	1.3	8
982	Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	12
983	Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-world Standard of Care in Patients With BRAF-Mutated Advanced Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100324.	0.6	0
984	Discovery of SHR2415, a Novel Pyrrole-Fused Urea Scaffold ERK1/2 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 701-706.	1.3	1
985	Triplet Therapy in Melanoma – Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies. <i>Current Oncology Reports</i> , 2022, 24, 1071-1079.	1.8	11
986	Revisiting metallodrugs for the treatment of skin cancers. <i>Coordination Chemistry Reviews</i> , 2022, 462, 214506.	9.5	11
987	Fast reaction and long duration – application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report. <i>Chinese Journal of Plastic and Reconstructive Surgery</i> , 2021, 3, 193-196.	0.1	0
989	A case of primary malignant melanoma of the esophagogastric junction with abscopal effect after nivolumab administration. <i>Surgical Case Reports</i> , 2021, 7, 253.	0.2	5
990	Not so “rare” – an example of malignant melanoma in India: report from a tertiary cancer centre. <i>Ecancermedicalscience</i> , 2021, 15, 1335.	0.6	1
991	Dabrafenib: A narrative drug review. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 537.	0.1	4
992	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, 1964-1975.	0.6	15

#	ARTICLE	IF	CITATIONS
993	Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 865656.	1.3	0
994	Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. <i>BMC Cancer</i> , 2022, 22, 417.	1.1	5
1015	Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?. <i>Dermatology</i> , 2022, 238, 517-526.	0.9	5
1016	Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors. <i>European Journal of Dermatology</i> , 2019, 29, 107-108.	0.3	1
1021	Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma. <i>Melanoma Research</i> , 2022, 32, 295-298.	0.6	4
1022	Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapyâ€”Present State and Perspectives. <i>Cancers</i> , 2022, 14, 2315.	1.7	7
1023	Trametinib for Refractory Chylous Effusions and Systemic Complications in Children with Noonan Syndrome. <i>Journal of Pediatrics</i> , 2022, 248, 81-88.e1.	0.9	15
1024	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases â€” A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12
1025	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.3	6
1026	Double Trouble: Immunotherapy Doublets in Melanomaâ€”Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 745-766.	1.8	6
1027	Prevalence and Clinicopathologic Features of Canine Metastatic Melanoma Involving the Central Nervous System: A Retrospective Analysis and Comparative Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1028	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. <i>Lung Cancer</i> , 2022, 169, 102-114.	0.9	8
1029	Cutaneous melanoma. , 2023, , 370-375.		0
1030	Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. <i>International Ophthalmology Clinics</i> , 2022, 62, 49-63.	0.3	6
1031	Application of histology-agnostic treatments in metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2022, 54, 1291-1303.	0.4	5
1032	Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	14
1033	Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy. <i>Cancers</i> , 2022, 14, 2992.	1.7	12
1034	Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	3



#	ARTICLE	IF	CITATIONS
1035	Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. <i>Cancer Letters</i> , 2022, 543, 215799.	3.2	3
1036	Targeting the Epigenome in Malignant Melanoma: Facts, Challenges and Therapeutic Promises. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1037	Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
1038	Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 4, .	0.1	0
1039	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1040	Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
1042	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. <i>Cancers</i> , 2022, 14, 3674.	1.7	3
1043	Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors. <i>JCO Precision Oncology</i> , 2022, , .	1.5	8
1044	Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1. <i>Cancer Research Communications</i> , 2022, 2, 1061-1074.	0.7	4
1045	Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1046	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e333-e465.	0.5	97
1047	Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3513-3526.	1.2	4
1048	Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. <i>Life</i> , 2022, 12, 1302.	1.1	5
1049	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal</i> , 2022, 43, 4229-4361.	1.0	705
1050	Immune Modulatory Effects of Molecularly Targeted Therapy and Its Repurposed Usage in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1768.	2.0	2
1051	The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition. <i>Cancer Letters</i> , 2022, 549, 215921.	3.2	13
1052	Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 110, 102463.	3.4	10
1053	Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism. <i>F1000Research</i> , 0, 11, 1081.	0.8	1

#	ARTICLE	IF	CITATIONS
1054	Dabrafenib plus trametinib in patients with relapsed/refractory <i>BRAF</i> V600E mutation-positive hairy cell leukemia. <i>Blood</i> , 2023, 141, 996-1006.	0.6	18
1055	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9985.	1.8	11
1056	Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy. <i>Genes</i> , 2022, 13, 1757.	1.0	4
1057	Anti-cancer agents and drug-induced hypertension. <i>Medical Alphabet</i> , 2022, , 30-41.	0.0	0
1059	Targeted Therapy and Immunotherapy in Melanoma. <i>Dermatologic Clinics</i> , 2023, 41, 65-77.	1.0	14
1060	Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. <i>Journal of Personalized Medicine</i> , 2022, 12, 1746.	1.1	5
1062	<i>BRAF</i> Inhibitors in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 4863.	1.7	4
1063	Comparison between antineoplastic treatments with selective inhibitors ( <i>BRAF</i> / <i>MEK</i> ) and the new potentials combinatorial therapies for metastatic melanoma. <i>Research, Society and Development</i> , 2022, 11, e326111436275.	0.0	0
1064	Melanoma classification and management in the era of molecular medicine. <i>Dermatologic Clinics</i> , 2023, 41, 49-63.	1.0	15
1065	New Directions in the Therapy of Glioblastoma. <i>Cancers</i> , 2022, 14, 5377.	1.7	23
1067	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. , 2022, 240, 108301.		9
1068	State of Art of LM Therapies: Intrathecal and Systemic Approaches. , 2022, , 101-124.		0
1069	Melanoma Treatment. <i>JACC: CardioOncology</i> , 2022, 4, 549-551.	1.7	0
1070	Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric <i>BRAF</i> V600E Mutant Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2023, 41, 664-674.	0.8	38
1071	Mutational status and clinical outcomes following systemic therapy with or without focal radiation for resected melanoma brain metastases. <i>World Neurosurgery</i> , 2022, , .	0.7	0
1072	Triple Combination of Immune Checkpoint Inhibitors and <i>BRAF</i> / <i>MEK</i> Inhibitors in <i>BRAF</i> V600 Melanoma: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 5489.	1.7	4
1073	Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?. <i>Expert Review of Anticancer Therapy</i> , 0, , .	1.1	0
1074	<i>PTEN</i> regulates invasiveness in pancreatic neuroendocrine tumors through <i>DUSP19</i> -mediated <i>VEGFR3</i> dephosphorylation. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	3

#	ARTICLE	IF	CITATIONS
1075	Upfront BRAF/MEK inhibitors for treatment of high-grade glioma-A Case Report and review of the literature. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	0
1077	BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. <i>Cancers</i> , 2023, 15, 141.	1.7	14
1078	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	1.8	6
1079	New Insights into the Phenotype Switching of Melanoma. <i>Cancers</i> , 2022, 14, 6118.	1.7	7
1080	A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1081	Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	0
1082	Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. <i>Neuro-Oncology</i> , 2023, 25, 1310-1320.	0.6	5
1084	Melanogenesis and the Targeted Therapy of Melanoma. <i>Biomolecules</i> , 2022, 12, 1874.	1.8	9
1085	Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	12
1086	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1087	Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy. <i>Annual Review of Cancer Biology</i> , 2023, 7, 247-263.	2.3	4
1088	KutanĀz Malign Melanom Nedeniyle Takip EttiĀyimiz HastalarĀn Klinikopatolojik Āzellikleri. <i>Turkish Journal of Clinics and Laboratory</i> , 0, , .	0.2	0
1089	Adjuvant therapies in stages IĀIII epidermal growth factor receptor-mutated lung cancer: current and future perspectives. <i>Translational Lung Cancer Research</i> , 2023, 12, 824-836.	1.3	2
1090	Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma. <i>Molecular Cancer Research</i> , 2023, 21, 397-410.	1.5	4
1091	The Evolution of the Sentinel Node Biopsy in Melanoma. <i>Life</i> , 2023, 13, 489.	1.1	1
1092	Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism. <i>F1000Research</i> , 0, 11, 1081.	0.8	0
1093	Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives. <i>Pharmaceutics</i> , 2023, 15, 1143.	2.0	13
1094	Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. <i>Oncologist</i> , 2023, 28, 327-332.	1.9	0

#	ARTICLE	IF	CITATIONS
1095	Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103919.	2.0	3
1096	Immunotherapy for Cutaneous Melanoma. , 2023, , 1-35.		0
1097	Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1098	BRAF v600E mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	4
1099	Current Trends in Mucosal Melanomas: An Overview. <i>Cancers</i> , 2023, 15, 1356.	1.7	5
1100	Oncolytic virus therapy for malignant gliomas: entering the new era. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 269-282.	1.4	8
1101	The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2023, 171, 83-94.	0.6	11
1102	Imaging Mass Spectrometry for the Classification of Melanoma Based on BRAF/NRAS Mutational Status. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5110.	1.8	1
1103	Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma. <i>Targeted Oncology</i> , 2023, 18, 235-245.	1.7	1
1104	Current Advances in Papillary Craniopharyngioma: State-Of-The-Art Therapies and Overview of the Literature. <i>Brain Sciences</i> , 2023, 13, 515.	1.1	5
1105	Melanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment. <i>Life</i> , 2023, 13, 828.	1.1	3
1106	Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , 2023, 50, 34-39.	0.8	2
1107	<i>In-silico</i> Molecular Docking and ADMET predictions of Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-Dione Analogues as promising Antimicrobial, Antioxidant and Anticancer agents. <i>Polycyclic Aromatic Compounds</i> , 0, , 1-18.	1.4	2
1108	High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
1109	Langerhans Cell Granulomatosis and Smoking-Related Interstitial Lung Diseases. , 2023, , 311-334.		0
1110	Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. <i>Nature Medicine</i> , 2023, 29, 1103-1112.	15.2	47
1111	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. <i>Pharmaceuticals</i> , 2023, 16, 614.	1.7	18
1113	Precision medicine-based cancer care. , 2024, , 272-283.		0

#	ARTICLE	IF	CITATIONS
1119	Clinical cases in neuro-oncology. , 2023, , 467-698.		0
1121	Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies. American Journal of Clinical Dermatology, 0, ,	3.3	0
1139	Precision Medicine. , 2023, , 199-214.		0
1150	Challenges and opportunities in rare cancer research in China. Science China Life Sciences, 2024, 67, 274-285.	2.3	0
1158	BRAF " a tumour-agnostic drug target with lineage-specific dependencies. Nature Reviews Clinical Oncology, 2024, 21, 224-247.	12.5	1